Justin Holko

Senior Vice President, Global Oncology/Hematology Commercial Business Unit · Regeneron Pharmaceuticals

Biopharmaceuticals

Justin Holko is senior vice president of the global oncology and hematology commercial business unit at Regeneron Pharmaceuticals. He joined in 2019 and previously led investor relations at the company, following nineteen years in cross-functional roles at Merck.

Last reviewed: Oct 21, 2026

Justin Holko

Senior Vice President, Global Oncology/Hematology Commercial Business Unit Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Justin Holko is senior vice president of the global oncology and hematology commercial business unit at Regeneron Pharmaceuticals. He joined in 2019 and previously led investor relations at the company, following nineteen years in cross-functional roles at Merck.

Career Highlights

  • Joined Regeneron in 2019.
  • Previously served as vice president of investor relations at Regeneron.
  • Now leads the global oncology and hematology commercial business unit.

Professional Journey

Holko spent nineteen years at Merck in roles of increasing cross-functional responsibility before joining Regeneron in 2019. The reviewed corporate biography does not provide titles or dates for the individual Merck assignments.

Within Regeneron, he previously served as vice president of Investor Relations. His current position leads the Global Oncology/Hematology Commercial Business Unit, extending his responsibilities into the company’s commercial oncology and hematology activities.

His team works on commercial growth, recruitment and development of employees, relationships with clinical opinion leaders and Regeneron brand awareness. These responsibilities support the business organization around the company’s cancer medicines. The company’s published biography identifies the commercial business remit rather than a clinical development position.

The move from investor relations into business-unit leadership is part of his documented internal progression, although a precise transition date is not supplied. His background combines an engineering degree with business education and pharmaceutical industry experience.

Education

Holko earned a BE from Vanderbilt University and an MBA from Rutgers University.